Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvoglustat in Pompe Disease
NCT00688597Phase 2Terminated
- Sponsor
- Amicus Therapeutics
- Start
- Dec 2008
- Primary completion
- Dec 2009
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label trial of duvoglustat in Pompe disease (3 cohorts), sponsored by Amicus Therapeutics. Primary endpoint: Proportion Of Participants Experiencing Severe Treatment-emergent Adverse Events at 11 weeks. Started Dec 2008; status: terminated.
02
Drugs
duvoglustat
03
Conditions
Pompe disease
Beyond the preview
Go deeper on NCT00688597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00688597.